Department of Pediatrics, Graduate School of Medicine, Kyoto University, Kyoto, Japan.
Japan Children's Cancer Group, Relapsed ALL Committee, Nagoya, Japan.
Cancer Sci. 2022 Nov;113(11):3814-3825. doi: 10.1111/cas.15506. Epub 2022 Aug 30.
A lack of practical resources in Japan has limited preclinical discovery and testing of therapies for pediatric relapsed and refractory acute lymphoblastic leukemia (ALL), which has poor outcomes. Here, we established 57 patient-derived xenografts (PDXs) in NOD.Cg-Prkdc ll2rg /ShiJic (NOG) mice and created a biobank by preserving PDX cells including three extramedullary relapsed ALL PDXs. We demonstrated that our PDX mice and PDX cells mimicked the biological features of relapsed ALL and that PDX models reproduced treatment-mediated clonal selection. Our PDX biobank is a useful scientific resource for capturing drug sensitivity features of pediatric patients with ALL, providing an essential tool for the development of targeted therapies.
日本缺乏实用资源,限制了儿科复发和难治性急性淋巴细胞白血病 (ALL) 的治疗方法的临床前发现和测试,而该病的预后较差。在这里,我们在 NOD.Cg-Prkdc ll2rg /ShiJic (NOG) 小鼠中建立了 57 个患者来源的异种移植 (PDX),并通过保存包括三个髓外复发 ALL PDX 在内的 PDX 细胞创建了一个生物库。我们证明,我们的 PDX 小鼠和 PDX 细胞模拟了复发 ALL 的生物学特征,并且 PDX 模型再现了治疗介导的克隆选择。我们的 PDX 生物库是捕获儿科 ALL 患者药物敏感性特征的有用科学资源,为靶向治疗的发展提供了重要工具。